TelevettedTELEVETTED
Menu
← Back to Recovery & peptides

Recovery & peptides · Claim check

The BPC-157 + TB-500 “Wolverine stack” is not covered by the new policy

Both peptides are on the October 28 list. Mixed in one vial, they aren't. Here is what the policy says about TB-500, blends and routes.

Updated November 1, 20265 min readEditorial review
Reader noteTreatment decisions belong with a licensed clinician who knows your history.

THE BOTTOM LINE

The October 28 policy covers BPC-157 and TB-500 separately, and only as single-ingredient products. A compounded vial combining them is outside the policy. TB-500 is covered only as a subcutaneous or intramuscular injection. Neither has controlled human trials showing faster injury recovery, and both are banned in WADA-tested sport.

SIDE-BY-SIDE

What actually differs

FactorBPC-157TB-500
On the Oct 28 listYes (acetate)Yes (acetate)
Covered routesSubcutaneous, intramuscular, oral, topicalSubcutaneous or intramuscular injection only
Blends coveredNoNo
Human trials for injury recoveryVery few, smallNone for the fragment
WADA statusProhibited (S0)Prohibited (S2)

Why blends fall outside the policy

One of the policy's conditions is that the compounded product contains a single active ingredient. That rules out the pre-mixed BPC-157 + TB-500 product that dominated the gray market, as well as similar multi-peptide blends. A pharmacy could, in principle, compound each one on its own for a patient whose clinician prescribes both.

What TB-500 actually is

TB-500 is a synthetic fragment associated with thymosin beta-4. Most of the interest comes from animal wound-healing research. FDA reviewers found no human safety studies for TB-500 in documents for the July 2026 advisory meeting, and FDA has previously flagged possible risks for both peptides.

QUICK ANSWERS

Can a pharmacy compound BPC-157 and TB-500 together?

Not under the October 28 HHS policy. It covers single-ingredient products only, so blends are excluded.

Is TB-500 legal now?

TB-500 acetate is one of the six peptides in the October 28 policy, covered only as a subcutaneous or intramuscular injection compounded by a licensed pharmacy or physician under the policy conditions. It is not FDA approved.

PRIMARY & AUTHORITATIVE SOURCES

Check the underlying record

Federal Register: HHS enforcement discretion policy, 503A peptide compounding (public inspection)↗HHS policy appendix B (PDF)↗Frier Levitt: what the peptide policy covers, by route↗Doctronic: what the October 2026 HHS change means↗Holland & Knight: PCAC votes on seven peptides↗
Regulatory status and labeling can change. Sources were reviewed on the article update date; current prescribing information controls.

PROVIDER TO CHECK

Live Vital

A physician-supervised telehealth company offering compounded BPC-157 under the October 28 policy, with treatment decisions made by a licensed clinician. Run it through the seven questions on our BPC-157 review before you start.

Check BPC-157 eligibility at Live Vital →Televetted may earn a commission if you sign up through this link. Payment never changes the facts we report. This is not a rating under the Televetted Method.

RELATED

Evidence reviewBPC-157 after the October 28 policy: what changed, what didn't, and how to check a providerLegal statusIs BPC-157 legal now? The honest answer after October 28How toHow to get BPC-157 through telehealth, and what a legitimate provider looks likeComparisonResearch-use-only vs. pharmacy-compounded BPC-157: why the label matters nowComparisonOral vs. injectable BPC-157: which forms the policy covers, and what to ask

COMPARE THE CARE MODEL

Medication is only one part of the decision.

Use the 30-second filter to identify the costs, clinical safeguards and service terms worth checking before you enroll.

Find my starting point →